648 / 1266
• Cure is probably restricted to younger patients
=> cure might even be achieved when the tumor recurs
• Standard of care is only poorly defined
=> further trials are urgently needed
• Whenever possible, HD-MTX should be administered
• Avoid WBRT when possible
• Open questions:
• Role for rituximab?
• Optimal treatment for elderly/frail patients?
Conclusions